3 . Marrow aspiration and biopsy within 2 weeks prior 
to study entry studies for staging, cytogenetics, 
clonogenic assays, PCR, FACS. 
4. EKG 
5. Pulmonary function tests with arterial blood gases 
(spirometry, DLCO) . 
6. Cardiac Gated blood pool scan (MUGA) 
Laboratory Evaluation 
1. CBC, platelet count, reticulocyte count, 
differential, type and screen, direct Coomb's, 
PTT, Prothrombin time, U/A 
2. Ca, P04 , Mg, total protein, albumin, electrolytes, 
LFT's glucose, BUN and creatinine. 
3 . HIV antibody 
4. HLA type (A+B antigens) and HLA antibody screen, 
PRA or other antibody screen 
5 . Quantitative immunoglobulin 
6. Herpes simplex screen (prior to admission) 
7. Hepatitis screen (prior to admission) 
8 . CMV screen 
9 . 0 On-study Evaluation 
9.1 Studies During Interferon Therapy 
Once the patient has acheived a stable dose level, 
recommend follow-up monthly with bimonthly CBC, 
differential and platelet count and q 3 month marrow 
aspirate/cytogenetics . 
9 . 2 Studies Prior to Cytoreductive Therapy and Recovery 
Phase/ Stem Cell Harvest 
1. Routine admission labs (see on-study evaluation 
flow diagram, appendix H) . 
3. Marrow aspiration/biopsy/cytogenetics will be 
obtained immediately prior to cytoreductive 
therapy. A marrow aspirate/cytogenetics will be 
obtained during the recovery phase from 
[166] 
Recombinant DNA Research, Volume 16 
